Allergan

MARLOW, England, July 27, 2011 - Allergan announces today that the National Institute for Health and Clinical Excellence (NICE) has issued final guidance recommending OZURDEX (dexamethasone 0.7mg intravitreal implant in applicator) for the treatment of macular oedema due to central retinal vein occlusion (CRVO) and also for branch retinal vein occlusion (BRVO) where laser photocoagulation is neither beneficial nor appropriate.

MARLOW, England, June 8, 2011 - - First Patient to be Enrolled in Comparison of Intravitreal Dexamethasone Implant and Ranibizumab for Macular Oedema in BRVO (COMO) Study This Summer Allergan Ltd.

MARLOW, England, June 6, 2011 - Allergan announces today that the National Institute for Health and Clinical Excellence (NICE) has recommended OZURDEX(R) (dexamethasone 0.7mg intravitreal implant in applicator) for the treatment of macular oedema due to central retinal vein occlusion (CRVO) and also for branch retinal vein occlusion (BRVO) where laser photocoagulation is neither beneficial nor appropriate.

LONDON - - Medical Experts Call for Greater Consideration of Gastric Banding for Obese People With Type 2 Diabetes LONDON, July 1 /PRNewswire/ -- Allergan's LAP-BAND(TM) AP System for obesity intervention has become the first device to receive official European approval for weight loss that leads to improvement or remission of type 2 diabetes.